Esperion Therapeutics Inc (NASDAQ: ESPR) is -50.45% lower on its value in year-to-date trading and has touched a low of $0.69 and a high of $3.94 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ESPR stock was last observed hovering at around $1.17 in the last trading session, with the day’s loss setting it -0.08%.
Currently trading at $1.09, the stock is 6.56% and 12.44% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.36 million and changing -6.84% at the moment leaves the stock -38.01% off its SMA200. ESPR registered -62.54% loss for a year compared to 6-month loss of -57.25%.
The stock witnessed a 35.94% gain in the last 1 month and extending the period to 3 months gives it a -31.01%, and is -10.66% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.16% over the week and 5.13% over the month.
Esperion Therapeutics Inc (ESPR) has around 304 employees, a market worth around $216.03M and $259.57M in sales. Profit margin for the company is -59.03%. Distance from 52-week low is 57.40% and -72.34% from its 52-week high. The company has generated returns on investments over the last 12 months (-288.75%).
The EPS is expected to grow by 45.54% this year.
Esperion Therapeutics Inc (ESPR) Top Institutional Holders
The shares outstanding are 196.66M, and float is at 194.58M with Short Float at 13.54%.
The top institutional shareholder in the company is WASATCH ADVISORS LP with over 16.86 million shares valued at $37.44 million. The investor’s holdings represent 8.9319% of the ESPR Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 13.98 million shares valued at $31.04 million to account for 7.4068 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 10.82 million shares representing 5.7294% and valued at over $24.01 million, while BELLEVUE GROUP AG holds 5.2672 of the shares totaling 9.94 million with a market value of $22.08 million.
Esperion Therapeutics Inc (ESPR) Insider Activity
Still, SEC filings show that on Jun 17 ’25, Looker Benjamin (Officer) Proposed Sale 6,422 shares at an average price of $1.15 for $7398.0. The insider now directly holds shares of Esperion Therapeutics Inc (ESPR).
